Asia Pacific Vaccines Market
시장 규모 (USD 10억)
연평균 성장률 :
% 
 예측 기간 |
2023 –2030 |
 시장 규모(기준 연도) |
USD 9,048.51 Million |
 시장 규모(예측 연도) |
USD 18,031.69 Million |
 연평균 성장률 |
% |
| 주요 시장 플레이어 |
Asia-Pacific Vaccines Market, By Composition (Combination Vaccines and Mono Vaccines), Type (Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines, Live-Attenuated Vaccines, Inactivated Vaccines, and Toxoid Vaccines), Kind (Routine Vaccine, Recommended Vaccine, and Required Vaccine), Age of Administration (Pediatric Vaccine and Adult Vaccine), Diseases (Pneumococcal Disease, Measles, Mumps & Varicella, DPT, Hepatitis, Influenza, Typhoid, Meningococcal, Rabies, Japanese Encephalitis, Yellow Fever, and Others), Route of Administration (Injectable, Oral, and Nasal), End User (Community Hospitals, Hospitals, Specialty Centres, Clinics, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) - Industry Trends and Forecast to 2030.
Asia-Pacific Vaccines Market Analysis and Insights
The increasing prevalence of infectious diseases, including bacterial and viral diseases, provides the market with lucrative growth. Along with this, increasing government support and launching newer vaccines are also boosting the vaccine market. Another factor boosting the vaccine market growth is increasing vaccination awareness and demand for effective COVID-19 vaccines.
The Asia-Pacific vaccines market is expected to grow in the forecast period of 2023 to 2030. Data Bridge Market Research analyses that the market is growing with a CAGR of 9.4% in the forecast period of 2023 to 2030 and is expected to reach USD 18,031.69 Million by 2030 from USD 9,048.51 million in 2022.
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customisable to 2015-2020) |
|
Quantitative Units |
Revenue in USD Million |
|
Segments Covered |
By Composition (Combination Vaccines and Mono Vaccines), Type (Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines, Live-Attenuated Vaccines, Inactivated Vaccines, and Toxoid Vaccines), Kind (Routine Vaccine, Recommended Vaccine, and Required Vaccine), Age of Administration (Pediatric Vaccine and Adult Vaccine), Diseases (Pneumococcal Disease, Measles, Mumps & Varicella, DPT, Hepatitis, Influenza, Typhoid, Meningococcal, Rabies, Japanese Encephalitis, Yellow Fever, and Others), Route of Administration (Injectable, Oral, and Nasal), End User (Community Hospitals, Hospitals, Specialty Centres, Clinics, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) |
|
Countries Covered |
Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, and Rest of Asia-Pacific |
|
Market Players Covered |
Bharat Biotech, Biological E Limited, Bio Farma, Serum Institute of India Pvt. Ltd., Takeda Pharmaceutical Company Limited, Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.), Abbott, AstraZeneca, Sanofi, Pfizer Inc., Janssen Global Services, LLC (a subsidiary of Johnson & Johnson Services, Inc.), F. Hoffmann-La Roche Ltd, Panacea Biotec Ltd, and BAXTER VACCINES (a subsidiary of Baxter), among others |
Market Definition of Asia-Pacific Vaccines Market
Vaccines are product that stimulates the individual immune system to induce immunity against a particular disease. Vaccines work on the principle of memory and recognition. When weakened or killed microbes are injected into a body, these microbes cause B cells, memory cells of the immune system, to recognize the pathogen. In the future, if the same pathogen attacks the body, it works against those. Vaccines have been discovered for infectious diseases, including pneumococcal disease, measles, mumps, rubella, hepatitis, influenza, typhoid, varicella, and rabies.
Vaccines are of two types: combination vaccines (containing different strains of the pathogen) and monovaccines (containing a single strain of the pathogen). Different kinds of vaccines have been developed based on the material extracted from the pathogen, which can be polysaccharide coat, DNA, RNA, and the whole organism, either inactivated or live.
These are the vaccines that resulted in the eradication of diseases such as polio. As per the preference and efficiency of vaccines, these can be injected via several routes of administration that can be injectable, oral, or nasal. However, the injectable route of vaccine administration is highly preferred as it induces a systemic response. Vaccination can be achieved at hospitals, community clinics, and specialty clinics, among others, by trained personnel having appropriate knowledge about vaccine administration devices.
The increasing prevalence of infectious diseases, including bacterial and viral diseases, provides the market with lucrative growth. Along with this, increasing government support and the launch of newer vaccines also boost the vaccine market. Another factor boosting the vaccine market growth is increasing vaccination awareness and demand for effective COVID-19 vaccines.
Asia-Pacific Vaccines Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
DRIVERS
GROWTH IN THE IMMUNIZATION PROGRAMS AND CAMPAIGNS
Immunization programs and campaigns are increasing worldwide because of an increasing number of chronic diseases. As hepatitis, diphtheria, pertussis, and polio, among other infectious diseases, are prevailing in the environment, there is an urgent need to increase awareness regarding vaccination which can be achieved by launching several campaigns and programs. This has been reported that the number of immunization programs is increasing with an increase in infectious diseases. Immunization coverage is also increasing worldwide, intending to fight against debilitating diseases.
Still, around 20 million people remain unvaccinated and under-vaccinated, raising a great demand for vaccination. The prevalence of chronic diseases is increasing worldwide. Hence the need to get vaccinated is great. This signifies that a growing immunization program and the campaign are expected to grow the vaccine market.
HIGH PREVALENCE OF CHRONIC CONDITIONS SUCH AS FLU, INFECTIOUS AND VIRAL DISEASES
The prevalence of infectious diseases is increasing worldwide, and this has been seen that flu and bacterial infectious disease are surging rapidly. This increasing rate of infectious diseases has created the need for disease prevention which can be prevented by vaccination or immunization. As diseases are increasing significantly, there is an urgent need for mass vaccination. Mass vaccinations require many diseases, hence expected to provide the vaccine market with lucrative growth.
As the disease cases are increasing, the focus on mass vaccination is also increasing to prevent large population size. Many people who have not received vaccination at a younger age are immunized worldwide. So, to cater such needs, the demand for novel vaccines is increasing and hence expected to act as a driver in the Asia-Pacific vaccines market.
RESTRAINT
UNAVAILABILITY OF REGISTERED VACCINES
The strict regulatory approvals and time taking development procedures for the vaccines are some of the factors that are responsible for the unavailability of registered vaccines. The regulatory authorities find difficulties in the vaccines' assessment, licensure, control, and surveillance. The world supply of vaccines is delayed due to these regulations.
Therefore, the regulation processes and document formation of the manufacturing companies in different countries can act as a restrain and hamper the growth of the vaccines market.
OPPORTUNITY
STRATEGIC INITIATIVES BY THE MARKET PLAYERS
Market players adopt various strategic initiatives in the vaccines market that involve expansion, collaboration, and acquisition. These initiatives allow them to increase the company's product portfolio, leading to market expansion and enhancing the product demand among customers, which ultimately allows the market players to earn maximum revenue.
As the demand for effective and novel vaccines is increasing worldwide, these strategic initiatives taken by top market players aim at enhancing business operations and earning more profitability in the market.
Various strategic initiatives adopted by the market players allowed them to expand its root in vaccines and earn more market growth. Thus, the market players operating in vaccines are adopting several strategic initiatives expected to act as an opportunity for the vaccine market growth.
CHALLENGE
SIDE EFFECTS CAUSED BY VACCINES
The vaccine is a medical product that helps in preventing different diseases. But sometimes, side effects arise due to the use of the vaccines. Some of them are mild side effects which are redness, soreness, or swelling at the injection site. But the adverse side effects of the vaccines are rare but are life-threatening.
The life-threatening side effects can give rise to fear in the population's mind. Moreover, it impacts the credibility of vaccine manufacturers, affecting product sales. This thus suggests that side effects caused by vaccines may hamper the growth of the vaccines market.
Recent Developments
- In October 2022, Indonesia Launched its First Home-Grown COVID-19 Vaccine. IndoVac vaccine has been developed jointly by Indonesia's state-owned pharmaceutical company Bio Farma and the Baylor College of Medicine, an independent health sciences center in Houston, Texas
- In November 2020, Merck Sharp & Dohme Corp., a Merck & Co., Inc. subsidiary, signed an agreement to acquire OncoImmune, a clinical-stage biopharmaceutical company. The OncoImmune Company is highly focused on the development of COVID-19 treatment options. Through this agreement, the company is expecting to develop new vaccine candidates
- In September 2020, Sanofi and GSK signed an agreement with the government of Canada to supply 72 million doses of COVID-19 vaccines. There is a high demand for COVID-19 vaccines, and the demand is increasing with the increasing pandemic. This agreement allowed the company to ensure future potential
Asia-Pacific Vaccines Market Scope
Asia-Pacific vaccines market is segmented into composition, type, kind, age of administration, diseases, route of administration, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
COMPOSITION
- Combination vaccines
- Mono vaccines
On the basis of composition, the Asia-Pacific vaccines market is segmented into combination vaccines and monovaccines.
TYPE
- Subunit, recombinant, polysaccharide and conjugate vaccines
- Live-attenuated vaccines
- Inactivated vaccines
- Toxoid vaccines
On the basis of type, the Asia-Pacific vaccines market is segmented into subunit, recombinant, polysaccharide, and conjugate vaccines, live-attenuated vaccines, inactivated vaccines, and toxoid vaccines.
KIND
- Routine vaccine
- Recommended vaccine
- Required vaccine
On the basis of kind, the Asia-Pacific vaccines market is segmented into routine vaccine, recommended vaccine, and required vaccine.
AGE OF ADMINISTRATION
- Pediatric vaccine
- Adult vaccine
On the basis of age of administration, the Asia-Pacific vaccines market is segmented into pediatric vaccine and adult vaccine
DISEASES
- Pneumococcal disease
- Measles, mumps & varicella
- DPT
- Hepatitis
- Influenza
- Typhoid
- Meningococcal
- Varicella
- Rabies
- Japanese encephalitis
- Yellow fever
- Others
On the basis of diseases, the Asia-Pacific vaccines market is segmented into pneumococcal disease, measles, mumps, and varicella, DPT, hepatitis, influenza, typhoid, meningococcal, rabies, Japanese encephalitis, yellow fever, and others.
ROUTE OF ADMINISTRATION
- Injectable
- Nasal
- Oral
On the basis of route of administration, the Asia-Pacific vaccines market is segmented into injectable, oral, and nasal.
END USER
- Community hospitals
- Hospitals
- Specialty centres
- Clinics
- Others
On the basis of end user, the Asia-Pacific vaccines market is segmented into community hospitals, hospitals, specialty centres, clinics, and others.
DISTRIBUTION CHANNEL
- Hospital pharmacy
- Retail pharmacy
- Online pharmacy
On the basis of distribution channel, the Asia-Pacific vaccines market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy.
Asia-Pacific Vaccines Market Regional Analysis/Insights
Asia-Pacific vaccines market is analyzed, and market size insights and trends are provided by country, composition, type, kind, age of administration, diseases, route of administration, end user, and distribution channel, as referenced above.
The countries covered in this market report are Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, and the rest of Asia-Pacific.
Japan is expected to dominate the Asia-Pacific vaccine market regarding market share and revenue and will continue to flourish its dominance during the forecast period. This is due to a rising preference for preventive health check-ups.
The country section of the report also provides individual market-impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of Global brands and their challenges faced due to competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Asia-Pacific Vaccines Market Share Analysis
The vaccines market competitive landscape provides details of a competitor. Details include company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points are only related to the companies' focus on the vaccine market.
Some of the major players operating in the Asia-Pacific vaccines market are Bharat Biotech, Biological E Limited, Bio Farma, Serum Institute of India Pvt. Ltd., Takeda Pharmaceutical Company Limited, Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.), Abbott, AstraZeneca, Sanofi, Pfizer Inc., Janssen Global Services, LLC (a subsidiary of Johnson & Johnson Services, Inc.), F. Hoffmann-La Roche Ltd, Panacea Biotec Ltd, and BAXTER VACCINES (a subsidiary of Baxter), among others.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA-PACIFIC VACCINES MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 COMPOSITION LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL MODEL
4.2 PORTER'S FIVE FORCES
4.3 EPIDEMIOLOGY
4.4 INDUSTRIAL INSIGHTS:
4.5 PIPELINE ANALYSIS
4.6 ASIA-PACIFIC VACCINES MARKET: SUPPLY CHAIN MANAGEMENT OF VACCINES
4.6.1 COLD CHAIN STORAGE:
4.6.2 PROCESS OF LOGISTICS
5 REGULATORY FRAMEWORK
5.1 JAPAN
5.2 CHINA
5.3 SOUTH KOREA
5.4 INDIA
5.5 AUSTRALIA
5.6 SINGAPORE
5.7 THAILAND
5.8 MALAYSIA
5.9 INDONESIA
5.1 VIETNAM
5.11 PHILIPPINES
5.12 REST OF ASIA-PACIFIC
5.12.1 TAIWAN
5.12.2 CAMBODIA
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 GROWING IMMUNIZATION PROGRAMS AND CAMPAIGNS
6.1.2 HIGH PREVALENCE OF CHRONIC CONDITIONS SUCH AS FLU, INFECTIOUS AND VIRAL DISEASES
6.1.3 IMPROVEMENT IN TREATMENT
6.1.4 LAUNCH OF NEWER VACCINES
6.1.5 INCREASING GOVERNMENT SUPPORT
6.2 RESTRAINTS
6.2.1 UNAVAILABILITY OF REGISTERED VACCINES
6.2.2 DIFFICULTIES ASSOCIATED WITH THE TRANSPORT AND PRODUCTION OF VACCINES
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS
6.3.2 PRESENCE OF PIPELINE PRODUCTS
6.3.3 RISE IN EXPENDITURE IN THE HEALTHCARE SECTOR
6.3.4 INCREASING AWARENESS FOR VACCINATION
6.4 CHALLENGES
6.4.1 SIDE EFFECTS CAUSED BY VACCINES
6.4.2 FEAR AMONG PATIENTS RELATED TO INJECTIONS AND NEEDLE STICKS
6.4.3 PRODUCT RECALL
7 ASIA-PACIFIC VACCINES MARKET, BY COMPOSITION
7.1 OVERVIEW
7.2 COMBINATION VACCINES
7.3 MONO VACCINES
8 ASIA-PACIFIC VACCINES MARKET, BY TYPE
8.1 OVERVIEW
8.2 SUBUNIT, RECOMBINANT, POLYSACCHARIDE, AND CONJUGATE VACCINES
8.2.1 PNEUMOCOCCAL DISEASE
8.2.2 HIB (HAEMOPHILUS INFLUENZA TYPE B) DISEASE
8.2.3 HPV (HUMAN PAPILLOMA VIRUS)
8.2.4 HEPATITIS B
8.2.5 MENINGOCOCCAL
8.2.6 SHINGLES
8.2.7 WHOOPING COUGH
8.2.8 OTHERS
8.3 LIVE-ATTENUTAED VACCINES
8.3.1 ROTAVIRUS
8.3.2 MEASLES
8.3.3 MUMPS
8.3.4 RUBELLA
8.3.5 SMALLPOX
8.3.6 YELLOW FEVER
8.3.7 OTHERS
8.4 INACTIVATED VACCINES
8.4.1 FLU (SHOT ONLY)
8.4.2 POLIO (SHOT ONLY)
8.4.3 HEPATITIS A
8.4.4 RABIES
8.4.5 OTHERS
8.5 TOXOID VACCINES
8.5.1 DIPHTHERIA, TETANUS & PERTUSSIS (DTP)
8.5.2 OTHERS
9 ASIA-PACIFIC VACCINES MARKET, BY KIND
9.1 OVERVIEW
9.2 ROUTINE VACCINES
9.2.1 PNEUMOCOCCAL DISEASES
9.3 DIPTHERIA, TETANUS & PERTUSIS(DPT)
9.3.1 HIB (HAEMOPHILUS INFLUENZA TYPE B) DISEASE
9.3.2 MEASLES
9.3.3 MUMPS
9.3.4 HEPATITIS B
9.3.5 RUBELLA
9.3.6 POLIO
9.3.7 OTHERS
9.4 RECOMMENDED VACCINE
9.4.1 TYPHOID FEVER VACCINE
9.5 HEPATITIS A
9.5.1 RABIES
9.5.2 JAPANESE ENCEPHALITIS
9.5.3 TICK-BORNE ENCEPHALITIS
9.5.4 CHOLERA
9.5.5 OTHERS
9.6 REQUIRED VACCINE
9.6.1 MENINGOCOCCAL
9.7 YELLOW FEVER
9.7.1 OTHERS
10 ASIA-PACIFIC VACCINES MARKET, BY AGE OF ADMINISTRATION
10.1 OVERVIEW
10.2 PEDIATRIC VACCINE
10.2.1 PNEUMOCOCCAL DISEASES
10.3 MEASLES, MUMPS & RUBELLA
10.3.1 DIPTHERIA, TETANUS & PERTUSIS (DPT)
10.3.2 ROTAVIRUS
10.3.3 MENINGOCOCCAL
10.3.4 VARICELLA
10.3.5 POLIO
10.3.6 TUBERCULOSIS
10.3.7 MALARIA
10.3.8 OTHERS
10.4 ADULT VACCINE
10.4.1 INFLUENZA
10.5 HPV (HUMAN PAPILLOMA VIRUS)
10.5.1 TYPHOID
10.5.2 HEPATITIS B
10.5.3 JAPANESE ENCEPHALITIS
10.5.4 YELLOW FEVER
10.5.5 CANCER
10.5.6 OTHERS
11 ASIA-PACIFIC VACCINES MARKET, BY DISEASES
11.1 OVERVIEW
11.2 PNEUMOCCOCAL DISEASE
11.3 MEASLES, MUMPS & RUBELLA
11.4 DPT
11.5 HEPATITIS
11.6 INFLUENZA
11.7 TYPHOID
11.8 MENINGOCOCCAL
11.9 VARICELLA
11.1 RABIES
11.11 JAPANESE ENCEPHALITIS
11.12 YELLOW FEVER
11.13 OTHERS
12 ASIA-PACIFIC VACCINES MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 INJECTABLE
12.2.1 INTRAMUSCULAR
12.2.2 SUBCUTANEOUS
12.2.3 INTRADERMAL
12.3 ORAL
12.4 NASAL
13 ASIA-PACIFIC VACCINES MARKET, BY END USER
13.1 OVERVIEW
13.2 COMMUNITY HOSPITALS
13.3 HOSPITALS
13.4 SPECIALTY CENTERS
13.5 CLINICS
13.6 OTHERS
14 ASIA-PACIFIC VACCINES MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 HOSPITAL PHARMACY
14.3 RETAIL PHARMACY
14.4 ONLINE PHARMACY
15 ASIA-PACIFIC VACCINE MARKET
15.1 ASIA-PACIFIC
15.1.1 JAPAN
15.1.2 CHINA
15.1.3 AUSTRALIA
15.1.4 INDIA
15.1.5 SOUTH KOREA
15.1.6 SINGAPORE
15.1.7 MALAYSIA
15.1.8 THAILAND
15.1.9 INDONESIA
15.1.10 PHILIPPINES
15.1.11 VIETNAM
15.1.12 REST OF ASIA PACIFIC
16 ASIA-PACIFIC VACCINES MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
16.2 DISEASE SHARE ANALYSIS: PFIZER, INC.
16.3 COUNTRY SHARE ANALYSIS: PFIZER, INC.
16.4 DISEASE SHARE ANALYSIS: MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.)
16.5 COUNTRY SHARE ANALYSIS: MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.)
16.6 DISEASE SHARE ANALYSIS: GLAXOSMITHKLINE PLC
16.7 COUNTRY SHARE ANALYSIS: GLAXOSMITHKLINE PLC.
16.8 DISEASE SHARE ANALYSIS: SANOFI
16.9 COUNTRY SHARE ANALYSIS: SANOFI
16.1 DISEASE SHARE ANALYSIS: SERUM INSTITUTE OF INDIA PVT. LTD.
16.11 COUNTRY SHARE ANALYSIS: SERUM INSTITUTE OF INDIA PVT. LTD.
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 PFIZER INC.
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 PRODUCT PORTFOLIO
18.1.4 RECENT DEVELOPMENTS
18.2 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.)
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY WEBSITE AND PRESS RELEASES
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 GLAXOSMITHKLINE PLC.
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 PRODUCT PORTFOLIO
18.3.4 RECENT DEVELOPMENTS
18.4 SANOFI
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 PRODUCT PORTFOLIO
18.4.4 RECENT DEVELOPMENTS
18.5 SERUM INSTITUTE OF INDIA PVT. LTD.
18.5.1 COMPANY SNAPSHOT
18.5.2 PRODUCT PORTFOLIO
18.5.3 RECENT DEVELOPMENTS
18.6 ABBOTT
18.6.1 COMPANY SNAPSHOT
18.6.2 REVENUE ANALYSIS
18.6.3 PRODUCT PORTFOLIO
18.6.4 RECENT DEVELOPMENTS
18.7 ASTRAZENECA (2022)
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENTS
18.8 ALK
18.8.1 COMPANY SNAPSHOT
18.8.2 REVENUE ANALYSIS
18.8.3 PRODUCT PORTFOLIO
18.8.4 RECENT DEVELOPMENTS
18.9 BAXTER VACCINES (A SUBSIDIARY OF BAXTER)
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENT
18.1 BHARAT BIOTECH
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENTS
18.11 BIO FARMA
18.11.1 COMPANY SNAPSHOT
18.11.2 PRODUCT PORTFOLIO
18.11.3 RECENT DEVELOPMENTS
18.12 BIOLOGICAL E LIMITED
18.12.1 COMPANY SNAPSHOT
18.12.2 PRODUCT PORTFOLIO
18.12.3 RECENT DEVELOPMENTS
18.13 DAIICHI SANKYO COMPANY, LIMITED
18.13.1 COMPANY SNAPSHOT
18.13.2 REVENUE ANALYSIS
18.13.3 PRODUCT PORTFOLIO
18.13.4 RECENT DEVELOPMENTS
18.14 F. HOFFMANN-LA ROCHE LTD
18.14.1 COMPANY SNAPSHOT
18.14.2 REVENUE ANALYSIS
18.14.3 PRODUCT PORTFOLIO
18.14.4 RECENT DEVELOPMENT
18.15 JANSSEN GLOBAL SERVICES, LLC (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
18.15.1 COMPANY SNAPSHOT
18.15.2 REVENUE ANALYSIS
18.15.3 PRODUCT PORTFOLIO
18.15.4 RECENT DEVELOPMENTS
18.16 LANZHOU BIOLOGICAL PRODUCTS RESEARCH INSTITUTE CO., LTD.,
18.16.1 COMPANY SNAPSHOT
18.16.2 PRODUCT PORTFOLIO
18.16.3 RECENT DEVELOPMENTS
18.17 PANACEA BIOTEC LTD
18.17.1 COMPANY SNAPSHOT
18.17.2 REVENUE ANALYSIS
18.17.3 PRODUCT PORTFOLIO
18.17.4 RECENT DEVELOPMENTS
18.18 SEQIRUS (A SUBSIDIARY OF CSL LIMITED)
18.18.1 COMPANY SNAPSHOT
18.18.2 REVENUE ANALYSIS
18.18.3 PRODUCT PORTFOLIO
18.18.4 RECENT DEVELOPMENTS
18.19 TAKEDA PHARMACEUTICAL COMPANY LIMITED
18.19.1 COMPANY SNAPSHOT
18.19.2 REVENUE ANALYSIS
18.19.3 COMPANY WEBSITE AND PRESS RELEASES
18.19.4 PRODUCT PORTFOLIO
18.19.5 RECENT DEVELOPMENTS
19 QUESTIONNAIRE
20 RELATED REPORTS
표 목록
TABLE 1 ASIA-PACIFIC VACCINES MARKET, PIPELINE ANALYSIS
TABLE 2 RECOMMENDED TEMPERATURE AND STORAGE LENGTH AT VARIOUS LEVELS OF THE COLD CHAIN.
TABLE 3 LOGISTICS PROCESS ACROSS DIFFERENT REGIONS.
TABLE 4 LAWS AND REGULATIONS IN TAIWAN
TABLE 5 VACCINES UNDER CLINICAL TRIAL
TABLE 6 THE SIDE EFFECTS RELATED TO THE VACCINES
TABLE 7 ASIA-PACIFIC VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION)
TABLE 8 ASIA-PACIFIC VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 9 ASIA-PACIFIC SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 10 ASIA-PACIFIC LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 11 ASIA-PACIFIC INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 12 ASIA-PACIFIC TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 13 ASIA-PACIFIC VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 14 ASIA-PACIFIC ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 15 ASIA-PACIFIC RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 16 ASIA-PACIFIC REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 17 ASIA-PACIFIC VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 18 ASIA-PACIFIC PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 19 ASIA-PACIFIC ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 20 ASIA-PACIFIC VACCINES MARKET, BY DISEASE, 2021-2030 (USD MILLION)
TABLE 21 ASIA-PACIFIC VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
TABLE 22 ASIA-PACIFIC INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
TABLE 23 ASIA-PACIFIC VACCINES MARKET, BY END USER, 2022-2030 (USD MILLION)
TABLE 24 ASIA-PACIFIC VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 25 ASIA-PACIFIC KNEE CARTILAGE REPAIR MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 26 JAPAN VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION)
TABLE 27 JAPAN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 28 JAPAN SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 29 JAPAN LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 30 JAPAN INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 31 JAPAN TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 32 JAPAN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 33 JAPAN ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 34 JAPAN RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 35 JAPAN REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 36 JAPAN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 37 JAPAN PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 38 JAPAN ADULT IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 39 JAPAN VACCINES MARKET, BY DISEASE, 2021-2030 (USD MILLION)
TABLE 40 JAPAN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 41 JAPAN INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 42 JAPAN VACCINES MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 43 JAPAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 44 CHINA VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION)
TABLE 45 CHINA VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 46 CHINA SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 47 CHINA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 48 CHINA INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 49 CHINA TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 50 CHINA VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 51 CHINA ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 52 CHINA RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 53 CHINA REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 54 CHINA VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 55 CHINA PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 56 CHINA ADULT IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 57 CHINA VACCINES MARKET, BY DISEASE, 2021-2030 (USD MILLION)
TABLE 58 CHINA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 59 CHINA INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 60 CHINA VACCINES MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 61 CHINA VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 62 AUSTRALIA VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION)
TABLE 63 AUSTRALIA VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 64 AUSTRALIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 65 AUSTRALIA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 66 AUSTRALIA INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 67 AUSTRALIA TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 68 AUSTRALIA VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 69 AUSTRALIA ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 70 AUSTRALIA RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 71 AUSTRALIA REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 72 AUSTRALIA VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 73 AUSTRALIA PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 74 AUSTRALIA ADULT IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 75 AUSTRALIA VACCINES MARKET, BY DISEASE, 2021-2030 (USD MILLION)
TABLE 76 AUSTRALIA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 77 AUSTRALIA INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 78 AUSTRALIA VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 79 INDIA VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION)
TABLE 80 INDIA VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 81 INDIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 82 INDIA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 83 INDIA INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 84 INDIA TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 85 INDIA VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 86 INDIA ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 87 INDIA RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 88 INDIA REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 89 INDIA VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 90 INDIA PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 91 INDIA ADULT IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 92 INDIA VACCINES MARKET, BY DISEASE, 2021-2030 (USD MILLION)
TABLE 93 INDIA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 94 INDIA INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 95 INDIA VACCINES MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 96 INDIA VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 97 SOUTH KOREA VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION)
TABLE 98 SOUTH KOREA VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 99 SOUTH KOREA SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 100 SOUTH KOREA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 101 SOUTH KOREA INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 102 SOUTH KOREA VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 103 SOUTH KOREA ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 104 SOUTH KOREA RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 105 SOUTH KOREA REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 106 SOUTH KOREA VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 107 SOUTH KOREA PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 108 SOUTH KOREA ADULT IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 109 SOUTH KOREA VACCINES MARKET, BY DISEASE, 2021-2030 (USD MILLION)
TABLE 110 SOUTH KOREA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 111 SOUTH KOREA INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 112 SOUTH KOREA VACCINES MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 113 SOUTH KOREA VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 114 SINGAPORE VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION)
TABLE 115 SINGAPORE SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 116 SINGAPORE LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 117 SINGAPORE INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 118 SINGAPORE TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 119 SINGAPORE VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 120 SINGAPORE ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 121 SINGAPORE RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 122 SINGAPORE REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 123 SINGAPORE VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 124 SINGAPORE PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 125 SINGAPORE ADULT IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 126 SINGAPORE VACCINES MARKET, BY DISEASE, 2021-2030 (USD MILLION)
TABLE 127 SINGAPORE VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 128 SINGAPORE INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 129 SINGAPORE VACCINES MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 130 SINGAPORE VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 131 MALAYSIA VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION)
TABLE 132 MALAYSIA VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 133 MALAYSIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 134 MALAYSIA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 135 MALAYSIA INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 136 MALAYSIA TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 137 MALAYSIA VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 138 MALAYSIA ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 139 MALAYSIA RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 140 MALAYSIA REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 141 MALAYSIA VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 142 MALAYSIA PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 143 MALAYSIA ADULT IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 144 MALAYSIA VACCINES MARKET, BY DISEASE, 2021-2030 (USD MILLION)
TABLE 145 MALAYSIA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 146 MALAYSIA INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 147 MALAYSIA VACCINES MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 148 MALAYSIA VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 149 THAILAND VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION)
TABLE 150 THAILAND VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 151 THAILAND SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 152 THAILAND LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 153 THAILAND INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 154 THAILAND TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 155 THAILAND VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 156 THAILAND RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 157 THAILAND REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 158 THAILAND VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 159 THAILAND PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 160 THAILAND ADULT IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 161 THAILAND VACCINES MARKET, BY DISEASE, 2021-2030 (USD MILLION)
TABLE 162 THAILAND VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 163 THAILAND INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 164 THAILAND VACCINES MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 165 THAILAND VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 166 INDONESIA VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION)
TABLE 167 INDONESIA VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 168 INDONESIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 169 INDONESIA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 170 INDONESIA INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 171 INDONESIA TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 172 INDONESIA VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 173 INDONESIA ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 174 INDONESIA RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 175 INDONESIA REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 176 INDONESIA VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 177 INDONESIA PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 178 INDONESIA ADULT IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 179 INDONESIA VACCINES MARKET, BY DISEASE, 2021-2030 (USD MILLION)
TABLE 180 INDONESIA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 181 INDONESIA INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 182 INDONESIA VACCINES MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 183 INDONESIA VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 184 PHILIPPINES VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION)
TABLE 185 PHILIPPINES VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 186 PHILIPPINES SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 187 PHILIPPINES LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 188 PHILIPPINES INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 189 PHILIPPINES TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 190 PHILIPPINES VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 191 PHILIPPINES ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 192 PHILIPPINES RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 193 PHILIPPINES REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 194 PHILIPPINES VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 195 PHILIPPINES PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 196 PHILIPPINES ADULT IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 197 PHILIPPINES VACCINES MARKET, BY DISEASE, 2021-2030 (USD MILLION)
TABLE 198 PHILIPPINES VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 199 PHILIPPINES INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 200 PHILIPPINES VACCINES MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 201 PHILIPPINES VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 202 VIETNAM VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION)
TABLE 203 VIETNAM VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 204 VIETNAM SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 205 VIETNAM LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 206 VIETNAM INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 207 VIETNAM TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 208 VIETNAM VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 209 VIETNAM ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 210 VIETNAM RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 211 VIETNAM REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 212 VIETNAM VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 213 VIETNAM PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 214 VIETNAM ADULT IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 215 VIETNAM VACCINES MARKET, BY DISEASE, 2021-2030 (USD MILLION)
TABLE 216 VIETNAM VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 217 VIETNAM INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 218 VIETNAM VACCINES MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 219 VIETNAM VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 220 REST OF ASIA-PACIFIC VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION)
그림 목록
FIGURE 1 ASIA-PACIFIC VACCINES MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC VACCINES MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC VACCINES MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC VACCINES MARKET: ASIA-PACIFIC VS COUNTRY MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC VACCINES MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC VACCINES MARKET: MULTIVARIATE MODELLING
FIGURE 7 ASIA-PACIFIC VACCINES MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 ASIA-PACIFIC VACCINES MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC VACCINES MARKET: SEGMENTATION
FIGURE 10 GROWING IMMUNIZATION PROGRAMS AND CAMPAIGNS AND THE HIGH PREVALENCE OF CHRONIC CONDITIONS SUCH AS FLU AND BACTERIAL INFECTIOUS DISEASES ARE DRIVING THE ASIA-PACIFIC VACCINES MARKET IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 11 THE COMBINATION VACCINES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC VACCINES MARKET IN 2023 & 2030
FIGURE 12 FDA REGULATORY REVIEW PROCESS OF VACCINES
FIGURE 13 PROCESS OF SPECIAL APPROVAL ON VACCINES DURING THE 2019 H1N1PDM PANDEMIC
FIGURE 14 REGULATION OVERVIEW FOR THERAPEUTICS IN SINGAPORE
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE ASIA-PACIFIC VACCINES MARKET
FIGURE 16 ASIA-PACIFIC VACCINES MARKET: BY COMPOSITION, 2022
FIGURE 17 ASIA-PACIFIC VACCINES MARKET: BY COMPOSITION, 2023-2030 (USD MILLION)
FIGURE 18 ASIA-PACIFIC VACCINES MARKET: BY COMPOSITION, CAGR (2023-2030)
FIGURE 19 ASIA-PACIFIC VACCINES MARKET: BY COMPOSITION, LIFELINE CURVE
FIGURE 20 ASIA-PACIFIC VACCINES MARKET: BY TYPE, 2022
FIGURE 21 ASIA-PACIFIC VACCINES MARKET: BY TYPE, 2023-2030 (USD MILLION)
FIGURE 22 ASIA-PACIFIC VACCINES MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 23 ASIA-PACIFIC VACCINES MARKET: BY TYPE, LIFELINE CURVE
FIGURE 24 ASIA-PACIFIC VACCINES MARKET: BY KIND, 2022
FIGURE 25 ASIA-PACIFIC VACCINES MARKET: BY KIND, 2023-2030 (USD MILLION)
FIGURE 26 ASIA-PACIFIC VACCINES MARKET: BY KIND, CAGR (2023-2030)
FIGURE 27 ASIA-PACIFIC VACCINES MARKET: BY KIND, LIFELINE CURVE
FIGURE 28 ASIA-PACIFIC VACCINES MARKET: BY AGE OF ADMINISTRATION, 2022
FIGURE 29 ASIA-PACIFIC VACCINES MARKET: BY AGE OF ADMINISTRATION, 2023-2030 (USD MILLION)
FIGURE 30 ASIA-PACIFIC VACCINES MARKET: BY AGE OF ADMINISTRATION, CAGR (2023-2030)
FIGURE 31 ASIA-PACIFIC VACCINES MARKET: BY AGE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 32 ASIA-PACIFIC VACCINES MARKET: BY DISEASES, 2022
FIGURE 33 ASIA-PACIFIC VACCINES MARKET: BY DISEASES, 2023-2030 (USD MILLION)
FIGURE 34 ASIA-PACIFIC VACCINES MARKET: BY DISEASES, CAGR (2023-2030)
FIGURE 35 ASIA-PACIFIC VACCINES MARKET: BY DISEASES, LIFELINE CURVE
FIGURE 36 ASIA-PACIFIC VACCINES MARKET: BY ROUTE OF ADMINISTRATION, 2022
FIGURE 37 ASIA-PACIFIC VACCINES MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
FIGURE 38 ASIA-PACIFIC VACCINES MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)
FIGURE 39 ASIA-PACIFIC VACCINES MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 40 ASIA-PACIFIC VACCINES MARKET: BY END USER, 2022
FIGURE 41 ASIA-PACIFIC VACCINES MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 42 ASIA-PACIFIC VACCINES MARKET: BY END USER, CAGR (2023-2030)
FIGURE 43 ASIA-PACIFIC VACCINES MARKET: BY END USER, LIFELINE CURVE
FIGURE 44 ASIA-PACIFIC VACCINES MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 45 ASIA-PACIFIC VACCINES MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 46 ASIA-PACIFIC VACCINES MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 47 ASIA-PACIFIC VACCINES MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 48 ASIA-PACIFIC VACCINE MARKET: SNAPSHOT (2022)
FIGURE 49 ASIA-PACIFIC VACCINE MARKET: BY COUNTRY (2022)
FIGURE 50 ASIA-PACIFIC VACCINE MARKET: BY COUNTRY (2023 & 2030)
FIGURE 51 ASIA-PACIFIC VACCINE MARKET: BY COUNTRY (2022 & 2030)
FIGURE 52 ASIA-PACIFIC VACCINE MARKET: BY COMPOSITION (2023-2030)
FIGURE 53 ASIA-PACIFIC VACCINES MARKET: COMPANY SHARE 2022 (%)
FIGURE 54 PFIZER, INC., ASIA-PACIFIC VACCINES MARKET: DISEASE SHARE 2022 (%)
FIGURE 55 PFIZER, INC., ASIA-PACIFIC VACCINES MARKET: COUNTRY SHARE 2022 (%)
FIGURE 56 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.) ASIA-PACIFIC VACCINES MARKET: DISEASE SHARE 2022 (%)
FIGURE 57 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.) ASIA-PACIFIC VACCINES MARKET: COUNTRY SHARE 2022 (%)
FIGURE 58 GLAXOSMITHKLINE PLC, ASIA-PACIFIC VACCINES MARKET: DISEASE SHARE 2022 (%)
FIGURE 59 GLAXOSMITHKLINE PLC, ASIA-PACIFIC VACCINES MARKET: COMPANY SHARE 2022 (%)
FIGURE 60 SANOFI, ASIA-PACIFIC VACCINES MARKET: DISEASE SHARE 2022 (%)
FIGURE 61 SANOFI ASIA-PACIFIC VACCINES MARKET: COUNTRY SHARE 2022 (%)
FIGURE 62 SERUM INSTITUTE OF INDIA PVT. LTD., ASIA-PACIFIC VACCINES MARKET: DISEASE SHARE 2022 (%)
FIGURE 63 SERUM INSTITUTE OF INDIA PVT. LTD. ASIA-PACIFIC VACCINES MARKET: COUNTRY SHARE 2022 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
